Navigate
X
    QualityStocks
  • 17 years ago

Targanta Therapeutics Corporation (NASDAQ: TARG)

Targanta Therapeutics Corporation (NASDAQ: TARG), a biopharmaceutical company, is dedicated to developing and commercializing innovative antibiotics that treat serious infections in the hospital and other institutional settings. The company’s lead antibiotic, oritavancin, is designed to treat serious gram-positive bacterial infections, including complicated skin and skin structure infections, or cSSSI, and bacteremia, a blood stream infection. Additionally, Targanta is developing multiple antibacterial agents, including an oral version of oritavancin targeting Clostridium difficile-related conditions. For further information, visit the Company’s web site at www.targanta.com.

Tags Rodman & Renshaw
Related Post
  1. QualityStocksNewsBreaks – Powering AI: Nicola Mining Inc.’s (TSX.V: NIM) (OTCQB: HUSIF) Copper Project Aligns with Data Center Surge

    As artificial intelligence (“AI”) continues to revolutionize industries, the infrastructure supporting its growth has become…

  2. Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Breaks Ground on REE Processing Facility, Pioneers Domestic Supply Chain

    The company announced the groundbreaking of its Louisiana Strategic Metals Complex (“SMC”) in Alexandria. The…

  3. NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

    The new FDA voucher program aims to speed approval of drugs aligned with national health…